16 December 2013 -- Scancell Holdings plc (‘Scancell’ or the ‘Company’), the developer of novel immunotherapies for the
treatment of cancer, notes Nottingham Trent University’s announcement that using Scancell’s Immunobody®
technology, they have unlocked a protein that could pave the way for future prostate cancer vaccinations.
The full text of Nottingham Trent University’s announcement follows:

SCIENTISTS UNLOCK PROSTATE CANCER PROTEIN IN MOVE WHICH COULD LEAD TO

UK scientists have identified how a specific region of a prostate-related protein can be used to trigger the
body’s immune response against prostate cancer. The study by scientists at Nottingham Trent University –
and published in the European Journal of Immunology – could pave the way for new and improved vaccines
for prostate cancer.

The work focused on the prostatic acid phosphatase (PAP) protein, which is present in more than 90% of
prostate tumours. Scientists were able to develop a new prostate cancer vaccination strategy utilising a
portion, or ‘epitope’ of this PAP protein – PAP 114 – which was capable of preventing and reducing tumour
growth in pre-clinical trials.

The team believes the study could lead to the development of new vaccines which are able to generate a
more specific, more efficient, faster and longer-lasting protective immune response against prostate cancer.
It might also mean that vaccines could be developed at a lower cost than currently, and with fewer potential
side effects, say the scientists, who are based in the university's John van Geest Cancer Research Centre.
Prostate cancer is the most common cancer in men in the UK – each year more than 10,000 men will die as
a result of prostate cancer and more than 40,000 will be diagnosed with the disease. Cases are rising among
men over 50 and the average age for men to be diagnosed is between 70 and 74.

Although cancer vaccines can be formulated in a number of different ways, the approach devised by the
scientists for this PAP vaccine would involve a series of injections.

Dr Stephanie McArdle, lead researcher based in Nottingham Trent University’s John van Geest Cancer
Research Centre, said: “Unfortunately for most cancers, the specific targets against which vaccination
strategies can be based are sometimes weak and relatively poor at inducing robust, protective anti-tumour
immune responses.

“Developing cancer vaccines that can overcome the capacity of tumours to ‘evade’ the immune system and
induce protective anti-tumour immunity is therefore essential for the development of new immunotherapies
for aggressive disease.

"Our findings demonstrate that PAP-114 is a promising candidate for further development of PAP-based anticancer
vaccine strategies. It induces characteristics that are consistent with anti-tumour protection; capable
of triggering an immune attack against prostate cancer cells and protecting against established prostate
tumours."

The epitopes of the PAP protein were delivered to the immune system using Scancell’s proprietary
ImmunoBody® technology.